Evidence map›Paper›PMID 42401587›Full record

ArticleNature communications2026

Signaling downstream of tumor-stroma interaction regulates mucinous colorectal adenocarcinoma apicobasal polarity.

Nicolas Pasquier, Meri Pelkonen, Elise Carraz-Billat, Aleksi Isomursu, Raphaël Merand, Hellyeh Hamidi, Jacques R R Mathieu, Jouni Härkönen, Gautier Follain, Christophe Desterke and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Nicolas Pasquier *Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Meri Pelkonen *Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Elise Carraz-BillatUniversité Paris-Saclay, Gustave Roussy, Inserm, UMR 1279 Tumor Cell Dynamics, 94805, Villejuif, France.
Aleksi IsomursuTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.ORCID http://orcid.org/0000-0001-6006-9163
Raphaël MerandUniversité Paris-Saclay, Gustave Roussy, Inserm, UMR 1279 Tumor Cell Dynamics, 94805, Villejuif, France.ORCID http://orcid.org/0000-0001-8946-7659
Hellyeh HamidiTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.ORCID http://orcid.org/0000-0003-4841-8927
Jacques R R MathieuUniversité Paris-Saclay, Gustave Roussy, Inserm, UMR 1279 Tumor Cell Dynamics, 94805, Villejuif, France.ORCID http://orcid.org/0009-0005-2239-6303
Jouni HärkönenTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Gautier FollainTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.ORCID http://orcid.org/0000-0003-0495-9529
Christophe DesterkeINSERM UMR-S1310, Hôpital Paul Brousse, Université Paris-Saclay, Villejuif, France.ORCID http://orcid.org/0000-0001-7679-2524
Zoé FusilierINSERM-U932, Immunity and Cancer, Institut Curie, Paris-Cité University, Paris, France.ORCID http://orcid.org/0009-0006-1681-879X
Junel SolisTurku Bioimaging, Åbo Akademi University and University of Turku, Turku, Finland.ORCID http://orcid.org/0000-0003-0972-5262
Irina BelayaTurku Bioimaging, Åbo Akademi University and University of Turku, Turku, Finland.ORCID http://orcid.org/0000-0001-7594-0679
Pasi KankaanpääTurku Bioimaging, Åbo Akademi University and University of Turku, Turku, Finland.
Valeria BarresiDepartment of Diagnostics and Public Health, University of Verona, Verona, 37134, Italy.
Mohamed-Amine BaniGustave Roussy, Département de Pathologie Morphologique, 94805, Villejuif, France.
Johanna ProtinUniversité Paris-Saclay, Gustave Roussy, Inserm, UMR 1279 Tumor Cell Dynamics, 94805, Villejuif, France.
Jérôme CartryUniversité Paris-Saclay, Gustave Roussy, Inserm, UMR 1279 Tumor Cell Dynamics, 94805, Villejuif, France.ORCID http://orcid.org/0000-0002-1693-1323
Sabrina BedjaUniversité Paris-Saclay, Gustave Roussy, Inserm, UMR 1279 Tumor Cell Dynamics, 94805, Villejuif, France.
Olav M AndersenDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.ORCID http://orcid.org/0000-0003-4226-3354
Klaus EleniusTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Florent PeglionUniversité Paris-Saclay, Gustave Roussy, Inserm, UMR 1279 Tumor Cell Dynamics, 94805, Villejuif, France. florent.peglion@gustaveroussy.fr.ORCID http://orcid.org/0000-0002-9364-9444
Fanny JaulinUniversité Paris-Saclay, Gustave Roussy, Inserm, UMR 1279 Tumor Cell Dynamics, 94805, Villejuif, France.ORCID http://orcid.org/0000-0002-5110-1800
Johanna IvaskaTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland. johanna.ivaska@utu.fi.ORCID http://orcid.org/0000-0002-6295-6556

Funding

Academy of Finland (Suomen Akatemia) 346131EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 101142305
6 · The paper itself

Abstract

Mucinous colorectal carcinoma (MUC CRC) metastasis to multiple organs, and to the peritoneum, is associated with poor prognosis. Disseminating MUC CRCs exhibit either conventional (apical-in) or inverted (apical-out) polarity that influence patient outcomes. Therefore, it is critical to identify how MUC CRC polarity is regulated. Here, we analyze patient-derived MUC CRC xenografts with either apical-in or apical-out polarity. Single-cell analyses reveal α2β1-integrin as a key collagen-binding receptor in these models. Collagen-α2β1-integrin interaction activates Src and upregulates SorLA, an endosomal sorting receptor. SorLA supports apical-in polarity by promoting integrin recycling and HER2/HER3 expression. We observe positive correlation between HER2, HER3 and SorLA in patient samples and higher HER2 expression in apical-in-presenting tissues. Clinically relevant HER2/HER3-targeting antibodies revert tumor sphere polarity, and impede collagen remodeling and adhesion to mouse peritoneum. This SorLA-integrin-HER2/HER3 axis could represent a MUC CRC-patient stratification approach and be relevant for other carcinomas with apical-out phenotypes.

Indexed as

Adenocarcinoma, MucinousCell PolarityColorectal NeoplasmsSignal TransductionAnimalsCell Line, TumorCollagenErb-b2 Receptor Tyrosine KinasesFemaleGene Expression Regulation, NeoplasticHumansMiceCollagenERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Identifiers

PMID42401587
PMCPMC13469138

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.